The FILKRI biosimilar US launch adds a short-acting option to the oncology supportive care range of Accord BioPharma, the US specialty division of Intas Pharmaceuticals. On 12 October 2026, the company announced the commercial launch of FILKRI (filgrastim-laha), a biosimilar to Neupogen, which is used to help the body recover white blood cells lowered by chemotherapy and certain other treatments.
Biosimilar launches rarely make headlines the way new drugs do, but they shape what hospitals buy and what patients pay. Here is what was announced, how the product is supplied and coded for billing, and the details that were not disclosed.
Key facts about the FILKRI biosimilar US launch
- Product: FILKRI (filgrastim-laha), a biosimilar to Neupogen (filgrastim), a short-acting granulocyte colony-stimulating factor (G-CSF).
- Company: Accord BioPharma, the US specialty division of Intas Pharmaceuticals, which manufactures the product end to end, according to the company.
- Launch date: announced 12 October 2026.
- Supply: prefilled syringes of 300 mcg per 0.5 mL and 480 mcg per 0.8 mL, in cartons of one or ten.
- Billing: CMS has assigned the permanent Q-code Q5172, effective 1 October 2026.
- Not disclosed: list price, interchangeability status and the exact FDA approval date.
What the FILKRI biosimilar US launch covers
Filgrastim stimulates the bone marrow to make neutrophils, white blood cells that fight infection. According to the company, FILKRI is indicated to reduce the incidence of febrile neutropenia in patients with nonmyeloid cancers receiving myelosuppressive chemotherapy; to speed neutrophil recovery after induction or consolidation chemotherapy for acute myeloid leukaemia; to shorten neutropenia after myeloablative chemotherapy followed by bone marrow transplant; to treat symptomatic congenital, cyclic or idiopathic neutropenia; and to improve survival after acute exposure to myelosuppressive radiation doses. Febrile neutropenia, fever with a dangerously low neutrophil count, is a serious chemotherapy complication, and the National Cancer Institute explains how infection risk is managed during cancer treatment.
FILKRI biosimilar US launch: approval and evidence base
The FDA approved FILKRI earlier this year. The company’s launch announcement says only January 2026, while its separate approval announcement is dated 17 February 2026, so we have not stated an exact approval date. Biosimilars are approved on a showing that they are highly similar to the reference product with no clinically meaningful differences, and the FDA’s biosimilars information describes the pathway. According to the company, two randomised studies in healthy adults compared FILKRI with Neupogen. One assessed pharmacokinetics and pharmacodynamics, and both assessed safety and immunogenicity. The company says they demonstrated biosimilarity and similar safety. The data are cited as on file, and we have not seen efficacy data in patients with cancer. This is normal for a biosimilar pathway, but it is the company’s account rather than something we have verified.
The prescribing information carries the standard G-CSF warnings, which include splenic rupture, acute respiratory distress syndrome, serious allergic reactions, sickle cell crises, glomerulonephritis, capillary leak syndrome and a possible risk of myelodysplastic syndrome or acute myeloid leukaemia in certain settings. It should not be given within 24 hours before or after cytotoxic chemotherapy, and anyone with a prior serious allergic reaction to G-CSF products should not receive it. This is a summary of the labelling, not medical advice.
Why Accord wants both options after the FILKRI biosimilar US launch
Accord already markets UDENYCA (pegfilgrastim-cbqv), a long-acting biosimilar to Neulasta. FILKRI gives the company a short-acting counterpart. The company states a goal of 20 US biosimilar launches by 2030. In our assessment, the practical value of the FILKRI biosimilar US launch lies in completing a basket that hospital pharmacies and oncology practices can contract for in a single negotiation, rather than in any clinical novelty. Executives were quoted calling the launch a significant milestone, and saying biosimilars give physicians more choice. Those are company statements.
Billing for the FILKRI biosimilar US launch: the Q5172 code
A permanent billing code matters more than it sounds. Under the Healthcare Common Procedure Coding System, a product-specific code lets providers bill and be reimbursed consistently across care settings. CMS assigned Q5172 to FILKRI effective 1 October 2026, which means the code was in place before the launch announcement. The company also mentions competitive pricing and co-pay assistance through its AccordCares programme, but gave no list price. Without a price, the savings a biosimilar might offer cannot be assessed. That is the biggest unknown for hospitals.
What the FILKRI biosimilar US launch means for hospitals and patients
For a hospital pharmacy, a new filgrastim biosimilar widens the field of products it can negotiate over. Competition among biosimilars has generally been associated with lower prices for biologic medicines, although the size of any saving depends on contracts and rebates that are not public, so we cannot say what it will be for this product. For patients, the immediate change is likely to be invisible: the choice of product is usually made by the prescriber or the pharmacy, and the company’s co-pay assistance may matter for those with commercial insurance. Patients should not switch products without their care team. In our assessment, the real test will be uptake over the coming quarters, which the announcement does not address.
What remains unanswered about the FILKRI biosimilar US launch
- The wholesale acquisition cost, and how it compares with Neupogen and other filgrastim biosimilars.
- Whether FILKRI has, or will seek, an interchangeability designation.
- Whether vials will be offered alongside prefilled syringes. The announcement mentions only syringes.
- The exact FDA approval date.
- How quickly hospitals and payers will move to it.
For related coverage, see our reports on the margins on cancer drugs in India, the Viatris and Pacira acquisition, the STERIS and Xodus Medical deal and the Bristol Myers radiopharmaceutical trial, or browse more pharmaceutical news.
Frequently asked questions
What is the FILKRI biosimilar US launch?
Accord BioPharma announced on 12 October 2026 that FILKRI (filgrastim-laha), a biosimilar to Neupogen, is now available in the United States.
What is FILKRI used for after the FILKRI biosimilar US launch?
To reduce febrile neutropenia and speed neutrophil recovery in several chemotherapy and neutropenia settings, according to the company.
Is FILKRI interchangeable with Neupogen?
The announcement did not state an interchangeability designation.
How is FILKRI supplied?
Prefilled syringes of 300 mcg per 0.5 mL and 480 mcg per 0.8 mL.
How much does the FILKRI biosimilar US launch cost patients?
No list price was disclosed. The company mentions co-pay assistance.
How we reported this: we relied on the company’s launch announcement of 12 October 2026 and its earlier approval announcement. Claims about evidence and goals are the company’s. Last updated: 13 October 2026. This article is news reporting and not medical advice.
[…] Phase 3 data in a rare liver disease, and the wider biosimilars market in our report on the US launch of the FILKRI biosimilar. More coverage is in our pharmaceutical […]